November 8, 2021 5:19pm
Deceleration of the sector’s motion is today’s buzz word
Pre-open indication results: 3 HITs, 1 MISS and 1 PUMPED
Financing News: Chinook Therapeutics (KDNY closed down -$1.77 and is down -$0.61 in the aftermarket) announced that it intends to offer and sell 6,000,000 shares
The Biostage (BSTG) Chronicles: closed +$0.07 after being “pumped” +$0.60 with “promoted” 7,082 shares traded after Friday’s flat $0.00 at $2.60 with 9,003 shares traded
If you’re looking for sector intel, ideas and facts or Insight in a volatile climate, RMi defines the extenuating factors of share pricing. Who else is tracking a broad representative index of cell and gene therapy equities – the facts are supported by real numbers?
The Dow closed UP 104.27 points (+0.29%); the S&P closed UP +4.17 points (+0.09%) while the Nasdaq closed UP +10.77 points (+0.07%)
Henry’omics:
Indexes rallied again to a new intraday record on Monday after Congress approved an infrastructure spending package.
Economic Data Docket: Investors await fresh inflation readings in the week ahead. The producer price index and consumer price index are slated for release on Tuesday and Wednesday
Note: Biostage (BSTG) pumped-up +$0.07 after being up +$0.60 with 7,082 shares traded after Friday’s flat $0.00 with 9,003 shares traded after Thursday’s flat at $2.60 with 82 shares traded, Wednesday’s down -$0.40 to $2.60 with 1,208 shares traded, r Tuesday’s -$0.10 to $3.00 with 200 shares traded, flat again $0.00 on Monday with 80 shares traded to $3.10 after last Friday’s 162 shares traded, Thursday’s 95 shares traded and last Wednesday’s move from -$0.40 with 216 shares traded until the “pump” was turned-on with 1,676 shares traded to close +$0.10 – where is the SEC?
RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what’s happening …
- Monday opened negative at 12/19, 3 flats and 1 acquired, stayed negative at the mid-day at 15/18, 3 flats, 1 flat and 1 acquired, ending with a negative close of 16/17, 2 flats and 1 acquired;
- Friday opened negative at 8/25, 1 flat and 1 acquired, stayed negative at the mid-day at 7/25, 2 flats and 1 acquired, ending with a negative close of 11/19, 4 flats and 1 acquired;
RegMed Investors’ (RMi) pre-open: “"Skip to My (The) Lou" after a record close, a sector decline, more LPS (loss-per-share) earnings this week. Remember, patience is a virtue not an investment factor.” … https://www.regmedinvestors.com/articles/12172
Pre-open indication results: 3 HITs: < Alnylam Pharmaceuticals (ALNY +$0.72), Editas Medicine (EDIT +$3.07), Intellia Therapeutics (NTLA +$0.59), > and 1 MISS < Sage Therapeutics (SAGE -$0.73) and 1 Pumped <Biostage (BSTG +$0.60),
Key Metric - volume:
Sector volume HIGHER with 9 of the 17-upside having higher than the 3-month average volume with LOW volume of 5 of 16-downside having higher than the 3-month average volume;
Stand-out Downside Volume:
- bluebird bio (BLUE -$2.45 with 6.335 shares traded after Friday’s -$3.17 with 6.11 m shares traded
There are clear winners and losers
Jumping with share pricing momentum (10 of 16):
- CRISPR Therapeutics (CRSP +$3.90 after Friday’s -$2.76),
- Editas Medicine (EDIT +$3.07),
- Ionis Pharmaceuticals (IONS +$1.19 after Friday’s -$0.94),
- Alnylam Pharmaceuticals (ALNY +$0.72 after Friday’s +$1.70),
- Intellia Therapeutics (NTLA +$0.59 after Friday’s +$1.54),
- AxoGen (AXGN +$0.58 after Friday’s +$0.52),
- uniQure NV (QURE +$0.30 after Friday’s -$0.78),
- Fate Therapeutics (FATE +$1.77),
- MiMedx (MDXG +$0.13 after Friday’s +$0.17),
- Biostage (BSTG +$0.07)
- Pluristem (+$0.07),
Hammered in today’s market (10 of 17):
- Vericel (VCEL -$2.95 after Friday’s -$2.61),
- bluebird bio (BLUE -$2.4 after Friday’s -$3.17),
- Chinook Therapeutics (KDNY -$1.77 and a proposed offering after Friday’s +$3.72),
- Ultragenyx (RARE-$0.74 after Friday’s -$2.00),
- Sage Therapeutics (SAGE -$0.73 after Friday’s -$1.53),
- Regenxbio (RGNX -$0.64 after Friday’s +$0.50),
- Fate therapeutics (FATE -$0.63),
- BioLife Solutions (BLFS -$0.59 after Friday’s -$4.73
- Cellectis SA (CLLS -$0.56),
- Sangamo Therapeutics (SGMO -$0.41 after Friday’s +$0.08),
Closing Flat:
- 1 –ReNeuron (RENE.L) and 1 - Stemline Therapeutics (STML) – acquired
Stats:
The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:
- Monday, the IBB closed up +0.44% and XBI closed down -0.62%
- Friday, the IBB closed down -3.02% and XBI closed down -1.412%
The CBOE Volatility Index (VVIX: INDEX) tracked:
- Monday was up +0.74 points or +4.49% at 17.22
- Friday was up +1.04 points or +6.74% at 16.48
November, the second month of Q4/21:
Monday (11/8) closed negative with 16 incliners,17 decliners, 1 flat and 1 acquired
Friday closed negative with 11 incliners, 19 decliners, 4 flat and 1 acquired
Thursday closed negative with 16 incliners, 17 decliners, 1 flat and 1 acquired
Wednesday closed positive with 28 incliners, 6 decliners and 1 acquired
Tuesday closed positive with 24 incliners, 8 decliners, 2 flats and 1 acquired
Monday (11/1) closed positive with 29 incliners, 3 decliners, 2 flats and 1 acquired
The BOTTOM LINE: the week is starting as the sector totally faded again!
Q3 earnings …
We are seeing to date,
- One (1) net income – Bellicum Pharmaceuticals (BLCM),
- Nineteen (19) net losses to date <uniQure (QURE), Alnylam Pharmaceuticals (ALNY), Regenxbio (RGNX), Sage Therapeutics SAGE), Ultragenyx Pharmaceuticals (RARE), Voyager Therapeutics (VYGR), Solid Biosciences (SLDB), Ionis Pharmaceuticals (IONS), CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), Caladrius Biosciences (CLBS), AxoGen (AXGN), Adverum Biotechnologies (ADVM), Verastem (VSTM), Global Blood Therapeutics (GBT), Fate Therapeutics (FATE), Sangamo Therapeutics (SGMO), Cellectis SA (CLLS) and Editas Medicine (EDIT)>
- Q3 earnings reporting season began the tug-of-war between share pricing that is softer than usual and the usual LPS (loss-per-share) to be less than estimates and expectations.
The stem, cell and gene therapy earnings remaining with Vericel (VCEL) and Applied Genetic Technologies (AGTC) on 11/9, BioLife Solutions BLFS) on 11/11 followed by Athersys (ATHX) and Brainstorm Cell Therapeutics (BCLI) coming 11/15 (to date).
Reiterating, “the stem, cell and gene therapy sector is still seen as vulnerable to extreme low volume moves in either direction, as share pricing risk stimulates their susceptibility!”
I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”
WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!
Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations? What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
